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Abstract
Background—Despite widespread use in HIV and hepatitis B virus (HBV) infection, the
effectiveness of tenofovir (TDF) has not been studied extensively outside of small HBV-HIV
coinfected cohorts. We examined the effect of prior lamivudine treatment (3TC) and other factors
on HBV DNA suppression with TDF in a multi-site clinical cohort of coinfected patients.
Methods—We studied all patients enrolled in the Centers for AIDS Research Network of
Integrated Clinical Systems cohort from 1996-2011 who had chronic HBV and HIV infection,
initiated a TDF-based regimen continued for ≥3 months and had on-treatment HBV
measurements. We used Kaplan-Meier curves and Cox-Proportional hazards to estimate time to
suppression (HBV DNA level <200 IU/ml or <1000 copies/ml) by selected covariates.
Results—Among 397 coinfected patients on TDF, 91% were also on emtricitabine or 3TC
concurrently, 92% of those tested were HBeAg-positive, 196 (49%) had prior 3TC exposure; 192
(48%) achieved HBV DNA suppression over a median of 28 months (IQR 13-71). Median time to
HBV DNA suppression was 17 months for those who were 3TC-naïve and 50 months for those
who were 3TC-exposed. After controlling for other factors, prior 3TC exposure, baseline HBV
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DNA level >10,000 IU/ml, and lower nadir CD4 count were independently associated with
decreased likelihood of HBV DNA suppression on TDF.
Conclusion—These results emphasize the role of prior 3TC exposure and immune response on
delayed HBV suppression on TDF.
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INTRODUCTION
The prevalence of chronic hepatitis B virus (HBV) infection in HIV-infected individuals is
estimated to be up to ten-fold higher than the general population in developed countries 1.
Patients coinfected with HBV and HIV often have higher HBV DNA levels and more rapid
progression to cirrhosis or hepatic decompensation than patients with HBV alone 2,3.
Coinfected individuals are also at greater risk of liver-related mortality compared to their
HBV or HIV monoinfected counterparts 4. Because effective cures for chronic HBV
infection are limited and spontaneous anti-HBs seroconversion occurs infrequently,
sustained HBV viral suppression remains the primary goal of current HBV treatment,
particularly since higher baseline HBV viral levels are associated with a higher incidence of
cirrhosis and hepatocellular carcinoma 5,6.
Tenofovir disoproxil fumarate (TDF) was first licensed for the treatment of HIV in 2001 and
is one of the most commonly prescribed nucleos(t)ide analogues in combination
antiretroviral therapy (ART). The efficacy of TDF as a potent antiviral agent against HBV
was first described in HBV-HIV coinfected patients, although much of these data comprised
small studies with short-term follow-up or retrospective analyses of coinfected subsets of
patients in treatment trials 7-10. Given the current paucity of alternative HBV therapies, it is
important to evaluate how TDF performs in real-world settings over long-term follow-up,
particularly in heterogeneous patient populations.
Outside clinical trial settings, many HBV-HIV coinfected patients have been exposed to
lamivudine (3TC), an antiviral agent active against HIV and HBV. However, 3TC has a low
genetic barrier for HBV resistance, leading to rapid development of HBV resistance when
3TC is used alone 11. In vitro data suggest 3TC resistance may impact the effectiveness of
TDF against HBV but the full significance of this finding in clinical practice settings
remains unknown 12,13. We studied a large cohort of HIV-infected individuals with chronic
HBV infection in routine care at eight clinical sites across the United States to examine the
effect of prior treatment with 3TC and other risk factors on HBV DNA suppression among
patients treated with TDF.
METHODS
Study Population
The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)
cohort includes over 27,000 HIV-infected adults in clinical care from 1995 to the present 14.
Institutional review boards at each site approved the study protocol.
We identified all patients enrolled in CNICS between January 1996 to September 2011 who
were coinfected with HBV, defined by the presence of a reactive HBV surface antigen or
positive plasma HBV DNA level, and studied those coinfected patients with detectable HBV
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DNA or reactive e antigen who initiated ART with a regimen containing TDF and had at
least one HBV DNA measurement during treatment.
Data Sources & Study Definitions
The CNICS data repository captures comprehensive clinical data that include standardized
diagnosis, medication, laboratory, and demographic information collected through
Electronic Health Records (EHR) and other institutional data systems at each site 14. Data
quality assessment is conducted at the sites prior to data transmission and at the time of
submission to the CNICS Data Management Core (DMC). After integration into the
repository, data undergo extensive quality assurance procedures and data quality issues are
reported to CNICS sites by the DMC to investigate and correct. Data from each site are
updated, fully reviewed, and integrated into the repository quarterly 14 (http://www.uab.edu/
cnics).
We examined the association between HBV suppression, demographic and clinical factors
including baseline HBV viral load and serum alanine aminotransferase (ALT) defined as
those closest and prior to TDF initiation. Hepatitis B e antigen (HBeAg) status was defined
as ever having tested positive. The FIB-4 index was calculated as: age (years) x serum
aspartate aminotransferase (U/L) / platelets (109/L) × (ALT [U/L]1/2). A FIB-4 score >3.25
has an estimated positive predictive value for advanced fibrosis (Ishak fibrosis score 4-6) of
65% 15. A positive HCV-antibody or HCV RNA level defined HCV infection. HBV DNA
suppression was defined as the first HBV DNA value less than or equal to 200 IU/ml (or
1000 copies/ml) after TDF initiation, a threshold chosen to accommodate the different
assays across sites.
Statistical Analysis
We examined whether time to HBV suppression after initiating TDF treatment differed
among persons who were previously exposed to 3TC compared to those who were 3TC-
naïve. Patients were observed from the date TDF treatment was initiated to the date of HBV
suppression, the end of initial treatment, last HBV measurement or death, whichever
occurred first.
We used log-rank tests to examine the association between HBV suppression and age, HIV
transmission risk factor, sex, race/ethnicity, nadir or baseline CD4 count (categorized as
<200, 200-350, 351-500, and >500 cells per cubic millimeter), baseline serum ALT >80 U/L
(twice 40 U/L, the upper range of normal), baseline HIV RNA (categorized as <10,000,
10,000-99,999, ≥100,000 copies/ml), HBeAg status, HCV infection status, baseline HBV
DNA level >10,000 IU/ml 16 and calendar year of TDF initiation. The association between
the aforementioned variables and the main predictor, prior 3TC exposure, was assessed
using Chi-squared tests for categorical variables and Wilcoxon rank-sum and t-tests for
continuous variables. Covariates associated with the outcome from bivariate analysis at the
p<0.05 level were evaluated for collinearity using Chi-squared and Spearman correlation
coefficients. Variables relevant to HBV suppression were included in the final model.
Kaplan-Meier estimates and Cox proportional hazards were used to describe time to HBV
DNA suppression and the effect of prior 3TC exposure, adjusting for age, nadir CD4 count,
HBV DNA level, race, ALT, and year of TDF initiation to control for secular trends in HIV
care over calendar time. Tests of proportional hazards were conducted to confirm
assumptions and ensure interpretability. All analyses were conducted in SAS version 9.2
(Cary, NC) and Stata version 11 (College Station, TX).
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Among 24,911 patients enrolled in the CNICS cohort between January 1996 and September
2011, 1,067 (4.3%) patients had chronic HBV infection. Of the 1,067 HBV coinfected
patients, 939 were treated with TDF for at least 3 months; 463 of these had HBV DNA
measurements on treatment, of which 66 were excluded because the baseline HBV DNA
was undetectable; for a final study cohort of 397 patients. Baseline characteristics of patients
missing HBV measurements were similar to those with HBV measurements aside from a
lower proportion with baseline ALT >80 U/L (17% vs 25%). As shown in Table 1, the
median age of the study cohort at the time of TDF initiation was 40 years, 51% of the
participants were white, 90% were men, 14% reported injection drug use as a risk factor for
HIV transmission and 18% of patients also had HCV infection. Nearly all (91%) of these
patients were also on concurrent 3TC or emtricitabine (FTC). The median nadir CD4 count
was 128 cells/mm3 and baseline HIV RNA was 16,865 copies/ml. The majority of evaluable
patients had baseline HBV DNA levels ≥10,000 IU/ml (79%) and/or positive HBeAg status
(92%). Forty-six (12%) patients had a baseline FIB-4 score >3.25 suggestive of advanced
fibrosis.
Prior Lamivudine (3TC)
Of the 397 patients studied, 196 (49%) had a history of 3TC exposure before the initiation of
TDF with a median duration on 3TC of 40 months (interquartile range (IQR), 16 to 74).
3TC-exposed patients had lower baseline HIV RNA values prior to the initiation of TDF
likely due to HIV treatment experience. FIB-4 scores were comparable across groups. A
higher proportion of patients with prior 3TC exposure were in care earlier in the HIV
epidemic. Consistent with this difference, 3TC-experienced patients tended to initiate TDF
earlier in calendar time than their naïve counterparts and had lower nadir CD4 counts than
3TC-naïve patients with median nadir CD4 count of 68 cells/mm3 compared with 179 cells/
mm3, respectively.
HBV DNA Suppression on TDF
We observed HBV DNA suppression to <200 IU/ml in 192 (48% of 397) patients. The
median time to suppression for the entire cohort was 28 months (IQR 13-71). Median time
to HBV DNA suppression was 17 months for those who were 3TC-naïve and 50 months for
those who were 3TC-exposed (Figure 1). As shown in Table 2, after adjusting for age,
nadir CD4, baseline HBV level, ALT, race and year of TDF initiation, 3TC-exposed patients
were significantly less likely to achieve suppression of HBV DNA during treatment with
TDF, with an adjusted hazard ratio (aHR) of 0.60 (95% confidence interval [CI] 0.42, 0.85);
p=0.004. In addition to prior 3TC exposure, a lower nadir CD4 count and higher baseline
HBV viral burden (HBV DNA >10,000 IU/ml) were independent predictors of delayed
HBV DNA suppression. Compared with patients whose nadir CD4 count were ≥500 cells/
mm3, patients with nadir CD4 <200 cells/mm3 were almost half as likely to suppress HBV
DNA while on TDF (aHR: 0.53 (95% CI 0.31, 0.88); p=0.02). The median time to HBV
suppression for patients whose nadir CD4 count was <200 cells/mm3 was 29 months
compared to 9 months for those whose CD4 nadir was ≥500 cells/mm3. Patients with
baseline HBV DNA levels >10,000 IU/ml were also less likely to suppress (aHR: 0.34 (95%
CI: 0.22, 0.53); p<0.001), with a median time to HBV suppression of 30 months compared
to 9 months for those with lower HBV DNA levels.
Later calendar year of TDF initiation and baseline ALT >80 U/L were also associated with
increased likelihood of HBV DNA suppression. A history of an AIDS-defining condition
was associated with HBV suppression and prior 3TC in unadjusted analyses, but was not
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significant in the multivariable model while nadir CD4 remained an independent predictor;
prior AIDS-defining condition was therefore not included in the final model. We found no
significant difference in HBV suppression between patients who were on TDF alone versus
combination therapy with TDF and 3TC or FTC. However, our ability to detect this
difference may have been limited as only 37 (9%) patients were on TDF alone for their
HBV infection at the start of therapy.
Of the 192 patients who achieved HBV suppression, 111 had at least two subsequent HBV
measures that enabled us to examine viral breakthrough. Seven of these patients had a
recurrent detectable HBV DNA on TDF (all but one with HBV DNA level ≥10,000 IU/ml),
between 12 and 87 months after TDF initiation. All but two had concurrent HIV suppression
at the time of breakthrough.
Among the 127 patients with positive HBeAg who had HBeAg retested on therapy, 30
(24%) had subsequent HBeAg loss, with no difference between groups defined by prior 3TC
or HBV suppression. A greater proportion of patients who suppressed their HBV DNA had
serum ALT <40 U/L at the end of follow-up than those who did not (68% versus 51%,
p=0.001). Those who suppressed were also less likely to have subsequent FIB-4 scores
>3.25 (7% versus 20%, p<0.001).
Sensitivity Analyses
Patients included in the analysis had a median of two (interquartile range, IQR 1-3) serum
HBV DNA measurements over a median of 15 months (IQR 7-30) while under observation.
While there was no difference in number of HBV measurements per patient across 3TC
exposure groups, the 3TC-naive group was assessed slightly more frequently. Median time
from start of TDF to first HBV measurement was 4 months for 3TC-naïve and 6.4 months
for 3TC-exposed patients (p=0.02). Median time between HBV follow-up measurements
was 4.8 months for 3TC-naïve and 7 months for 3TC-exposed patients (p<0.01). To address
whether or not this differential frequency could account for the observed difference in
median time until HBV suppression, we examined the proportion of 3TC-exposed and 3TC-
naïve patients who had HBV measurements before and after the median time to suppression
among 3TC-naïve patients (17 months). We found that 27% of 3TC-exposed and 32% of
3TC-naïve patients had an HBV measurement within 8 to 16 months (p=0.25) following
TDF initiation, 21% of 3TC-exposed and 22% of 3TC-naïve patients (p=0.81) had an HBV
measurement between 16 to 24 months. Thus, the 3TC-exposed and 3TC-naïve groups were
equally likely to be observed in the early follow-up period that included the median time to
suppression among 3TC-naïve patients.
To address the possibility that adherence to medications could have accounted for the
difference in time to HBV suppression, we conducted survival analysis on the subset of 250
patients who achieved HIV RNA suppression to <50 copies/ml by six months as a proxy for
adherence. Our results were robust in this subset of patients with an adjusted hazard ratio of
0.62 for HBV suppression with prior 3TC exposure (95% CI 0.40, 0.95, p=0.03). Notably,
the proportion of patients who achieved HIV RNA <50 copies/mL by six months was
comparable between groups defined by prior 3TC (50% among 3TC-naïve versus 48%
among 3TC-exposed, p=0.80).
DISCUSSION
We studied the long-term effectiveness of TDF combined with 3TC or FTC in the treatment
of HBV in a large cohort of HBV-HIV coinfected patients in routine clinical care. Ours is
the largest observational study to date of HIV-HBV coinfected patients on TDF. Among the
397 patients in our cohort who had HBV DNA assessed on TDF therapy, most of whom
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were HBeAg-positive, 48% achieved HBV suppression on TDF during a median of two
years – comparable to rates of suppression reported in longitudinal studies of HBeAg-
positive coinfected patients 7,17-19 and treatment-experienced HBV monoinfected patients 20
but lower than other prospective reports of coinfected patients 21, possibly due to the higher
prevalence of positive HBeAg and/or lower nadir CD4 in our cohort. HBV suppression was
durable among the subset of patients who continued to have HBV DNA measured and HBV
viral breakthrough was infrequent, consistent with other long-term studies of coinfected
patients17,22. Failure to achieve HBV DNA <200 IU/ml on TDF was independently
associated with a higher baseline HBV DNA level – a well-established finding in both HBV
monoinfected and coinfected patients 23,24. Notably, we found that lower nadir CD4 count
and a history of prior 3TC exposure are independent risk factors for lack of HBV
suppression on TDF.
Almost half of our cohort had prior 3TC exposure with a median duration of past therapy of
over three years. Prolonged 3TC monotherapy for HBV can result in the accumulation of
HBV mutations conferring resistance to 3TC in >90% coinfected patients after 4 years of
therapy 11,25. Although TDF has been shown to perform well in 3TC-resistant HBV
monoinfected 26,27 and coinfected 7 patients, we found that prior 3TC therapy was
significantly associated with decreased likelihood of HBV DNA suppression with TDF,
even after adjusting for potential confounding factors including CD4 count and baseline
HBV viral level. Although 3TC and TDF do not appear to share the same pathway for drug
resistance, cumulative mutations against 3TC may partially compromise TDF activity, as
noted in in vitro studies 12,13. Inadequate inhibition of HBV viral replication during
treatment with 3TC can also generate compensatory mutations and favor the selection of
viral quasispecies with better fitness 28,29. This genetic heterogeneity has been linked with
delayed response to TDF in coinfected patients 13.
Previous studies have reported a blunted HBV virologic response to TDF among 3TC-
experienced compared with 3TC-naïve, in both HIV-HBV coinfected patients 21,30 and
HBV-monoinfected patients 20. In a Spanish cohort of HIV-HBV coinfected patients, the
mean time to HBV suppression was approximately twice as long in 3TC-experienced
compared to 3TC-naïve patients 30. Other studies not reporting a difference were smaller
and had higher proportions of 3TC-experienced patients 7,9,31 that limited their ability to
detect such differences due to lack of heterogeneity.
We found nadir CD4 count to be an independent predictor of HBV suppression on TDF –
with greater likelihood of HBV suppression the higher the nadir CD4 count. Prior reports
have noted an association of lower nadir CD4 counts with HBV viremia on 3TC 11 and a
trend toward delayed response to TDF 18. Baseline CD4 count has also been shown to
influence HBV DNA decline among HIV-HBV coinfected patients on TDF 22 and
adefovir 32. Patients with greater CD4 count gains on ART appear to be more likely to
suppress HBV DNA on antiviral therapy 33. Immune status and restoration have also been
shown to predict the kinetics of HBeAg clearance 34 and probability of HBsAg clearance on
antiviral therapy 35, both important serologic benchmarks of HBV treatment success. These
results, including our own, emphasize the key role of the host immune response in antiviral
efficacy and clearance of HBV-infected hepatocytes 36. Our findings also complement
longitudinal studies that demonstrate greater liver-related mortality among HBV-HIV
coinfected patients with lower nadir CD4 in the ART era 4,37 and suggest that uncontrolled
HBV viremia in patients with more advanced HIV-mediated immunosuppression may
contribute to accelerated liver disease progression.
This study has several limitations. As with any observational study, our findings may have
been influenced by unmeasured factors. Information about 3TC resistance in those who were
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3TC-exposed was not available, and we were not able to assess the relationship between
HBV suppression on TDF and outcomes of liver disease severity or cause-specific mortality.
Data on outcomes of HBeAg or HBsAg seroconversion were also limited, and antibody to
hepatitis delta (HDV) data not available. Although we could not examine adherence to
medications directly, the significant difference in HBV DNA suppression observed between
groups defined by prior 3TC was robust in the subset of patients who achieved HIV
suppression in 6 months, suggesting that differential adherence did not account for our
findings. HBV DNA was also measured infrequently and inconsistently in this cohort,
reflecting clinical practice patterns 38. However, patients with baseline and follow-up HBV
measurements had similar baseline characteristics to those with missing values. The median
time from the start of TDF to first HBV measurement and median time between subsequent
follow-up measurements differed by only a few months between 3TC-naïve and 3TC-
exposed patients. In addition, the majority of patients were assessed by 17 months, which
was the median time to suppression among 3TC-naïve patients. Our finding that the 3TC-
exposed and 3TC-naïve group were equally likely to be observed in the early follow-up
period between 8 to 24 months suggests that the observed difference in median time until
HBV suppression was not due to differential frequency in HBV measurements. In addition,
results of logistical analysis that evaluated HBV DNA suppression by specific time points
were similar, suggesting that the timing of HBV testing did not influence our results.
In conclusion, we found that both low nadir CD4 count and prior 3TC treatment were
significantly associated with decreased likelihood of HBV DNA suppression among patients
treated with TDF after controlling for other factors. These results highlight the role of the
host immune response as well as prior antiviral exposure in long-term HBV treatment
effectiveness, and provide further support for initiation of ART at higher CD4 counts well
before significant immune compromise has occurred. Future research is needed regarding
interventions to increase the rate of HBV suppression in HBV-HIV coinfected patients and
the potential link between lack of HBV DNA suppression on therapy and clinical HBV
events.
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Table 1
Baseline Characteristics of the HBV-HIV Coinfected Study Population
Total (n=397) Prior 3TC (n=196) No Prior 3TC (n=201) P-value
Age, years (median, IQR) 40 (35-46) 40 (36-46) 40 (33-46) 0.20
Sex, male 357 (90) 176 (90) 181 (90) 0.93
Race
    White 204 (51) 104 (53) 100 (50)
    Black 170 (43) 87 (44) 83 (41)
    Other 23 (6) 5 (3) 18 (9) 0.02
HCV coinfection 71 (18) 41 (21) 30 (15) 0.12
HIV Risk factor
    MSM 250 (63) 123 (63) 127 (63)
    IDU 55 (14) 29 (15) 25 (12)
    Heterosexual 73 (18) 31 (16) 42 (21)
    Other 20 (5) 13 (6) 7 (4) 0.29
AIDS-defining condition 149 (50) 82 (59) 67 (42) < 0.01
Baseline CD4, cells/mm3 (median, IQR) 229 (89-392) 243 (102-393) 214 (75-391) 0.49
Nadir CD4, cells/mm3 (median, IQR) 128 (25-290) 68 (14-209) 179 (46-353) <0.01
Baseline HIV RNA, copies/ml
    <10,000 178 (46) 120 (63) 58 (30)
    10,000-100,000 119 (31) 40 (21) 79 (40)
    >100,000 89 (23) 31 (16) 58 (30) < 0.01
HBeAg-positive
* 294 (92) 166 (95) 126 (89) 0.12
Baseline HBV DNA, lU/ml
    <10,000 46 (21) 15 (17) 31 (23) 0.55
    10,000-100,000 27 (12) 11 (13) 16 (12)
    >100,000 149 (67) 62 (70) 87 (65)
Baseline ALT, U/L (median, IQR) 51 (32-83) 52 (32-75) 50 (34-98) 0.15
Baseline FIB-4 score >3.25 46 (12) 27 (14) 19 (9) 0.17
Concurrent FTC/3TC use 360 (91) 167 (85) 193 (96) <0.01
Time on study
^
, months (median, IQR)
15 (7-30) 19 (9-38) 12 (6-20) <0.01
Data are presented here as number (%) of patients for categorical variables unless otherwise noted.
3TC, lamivudine; IQR, interquartile range; HCV, hepatitis C virus; MSM, men who have sex with men; IDU, injection drug use; HBeAg, hepatitis
B e-antigen; ALT, alanine aminotransferase; FTC, emtricitabine.
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*
Among n=317 tested for HBeAg status.
^
Time on TDF until suppression or censoring.
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Table 2
Association of Lamividine Exposure and Other Factors with HBV Suppression during Treatment with
Tenofovir in Bivariate and Multivariable Cox Proportional Hazards Analyses
Variable Hazard ratio (95% CI) P-value Adjusted Hazard ratio (95% CI) P-value
3TC exposure 0.38 (0.28, 0.52) <0.01 0.60 (0.42, 0.85) <0.01
Age >40 years 1.31 (0.98, 1.75) 0.07 1.08 (0.81, 1.43) 0.62
Nadir CD4, cells/mm3 (Ref: ≥500)
    350-499 0.27 (0.17, 0.45) <0.01 0.58 (0.33, 1.01) 0.06
    200-349 0.26 (0.16, 0.42) <0.01 0.55 (0.32, 0.93) 0.03
    <200 0.21 (0.14, 0.31) <0.01 0.53 (0.31, 0.88) 0.02
HBV DNA level >10,000 lU/ml 0.25 (0.15, 0.40) <0.01 0.34 (0.22, 0.53) <0.01
Race (Ref: White)
    Black 0.72 (0.54, 0.97) 0.03 0.78 (0.56, 1.08) 0.14
    Other 1.30 (0.63, 2.63) 0.48 1.21 (0.60, 2.45) 0.61
Serum ALT >80 U/L 1.43 (1.05, 1.94) 0.02 1.56 (1.14, 2.15) 0.01
Calendar year of TDF start 1.3 (1.23, 1.39) <0.01 1.22 (1.14, 1.31) <0.01
CI, confidence interval; 3TC, lamivudine; Ref, reference category; HBV, hepatitis B; ALT, alanine aminotransferase; TDF, tenofovir.
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2015 May 01.
